Entrada director-linked fund sells 155K shares

Entrada Therapeutics director Kush Parmar reported indirect sales of 155,255 shares of Common Stock of Entrada Therapeutics, Inc., executed by investment entities he helps manage.

Rhea-AI Filing Summary

Entrada Therapeutics director Kush Parmar reported indirect sales of 155,255 shares of Common Stock of Entrada Therapeutics, Inc., executed by investment entities he helps manage. The shares were sold on August 6, 7, and 10, 2026 at weighted average prices in the $6.80–$7.20 per-share range. After these transactions, an affiliated fund, 5AM Opportunities I, L.P., is reported as indirectly holding 1,093,313 shares, with Parmar disclaiming beneficial ownership beyond his pecuniary interest.

Insider Trade Summary

Net Seller: 155,255 shares

Net Sell 4 txns

Insider PARMAR KUSH

Role Director

Sold 155,255 shs ($1.08M)

Type	Security	Shares	Price	Value
Sale	Common Stock F4, F2	92,444	$7.00	$647K
Sale	Common Stock F3	52,317	$6.85	$358K
Sale	Common Stock F1, F2	10,494	$7.00	$73K
holding	Common Stock F5	--	--	--

Holdings After Transaction: Common Stock — 2,691,337 shares (Indirect, By 5AM Ventures V, L.P.); Common Stock — 1,093,313 shares (Indirect, By 5AM Opportunities I, L.P.)

Footnotes (5)

1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.90 to $7.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
2. F2. Shares are held by 5AM Ventures V, L.P. ("5AM V"). 5AM Partners V, LLC ("5AM Partners") is the sole general partner of 5AM V. Kush M. Parmar, M.D., Ph.D. is a managing member of 5AM Partners and may be deemed to share voting and investment power over the shares held by 5AM V. Dr. Parmar disclaims beneficial ownership of the shares held by 5AM V except to the extent of his pecuniary interest therein.
3. F3. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $6.80 to $7.01 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
4. F4. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $6.84 to $7.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
5. F5. Shares are held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Kush M. Parmar, M.D., Ph.D. is a managing member of Opportunities GP and may be deemed to share voting and investment power over the shares held by Opportunities. Dr. Parmar disclaims beneficial ownership of the shares held by Opportunities except to the extent of his pecuniary interest therein.

Key Figures

Total shares sold: 155,255 shares Sale on 2026-08-10: 92,444 shares at $7.0000 per share Sale on 2026-08-07: 52,317 shares at $6.8500 per share +2 more

5 metrics

Total shares sold 155,255 shares Aggregate non-derivative Common Stock sales reported on August 6–10, 2026

Sale on 2026-08-10 92,444 shares at $7.0000 per share Indirect sale by 5AM Ventures V, L.P. attributed to Kush Parmar

Sale on 2026-08-07 52,317 shares at $6.8500 per share Indirect sale by 5AM Ventures V, L.P. attributed to Kush Parmar

Sale on 2026-08-06 10,494 shares at $7.0000 per share Indirect sale by 5AM Ventures V, L.P. with weighted average price range $6.90–$7.11

Indirect holdings after transactions 1,093,313 shares Common Stock held by 5AM Opportunities I, L.P. as of August 6, 2026

Key Terms

weighted average price, beneficial ownership, pecuniary interest, voting and investment power

4 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

beneficial ownership financial

"Dr. Parmar disclaims beneficial ownership of the shares held by 5AM V except"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

pecuniary interest financial

"disclaims beneficial ownership of the shares held by 5AM V except to the extent of his pecuniary interest therein"

voting and investment power financial

"may be deemed to share voting and investment power over the shares held"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Entrada Therapeutics (TRDA) insider Kush Parmar report in this Form 4?

Kush Parmar reported indirect sales of 155,255 Entrada Therapeutics shares by funds he helps manage. The transactions involved Common Stock and were executed over three days in August 2026 at weighted average prices near $7 per share.

Over what dates were the TRDA shares sold in this filing?

The reported TRDA share sales occurred on August 6, 7, and 10, 2026. Each day’s trades was reported separately, with weighted average sale prices disclosed in footnotes covering the different price ranges for the executed transactions.

What prices were received for the TRDA shares sold in these transactions?

The reported per-share prices are weighted averages, with trades executed in ranges of $6.80–$7.01, $6.84–$7.20, and $6.90–$7.11. The reporting person notes detailed trade breakdowns are available upon request to the company or regulators.

Were the TRDA shares sold directly by Kush Parmar or by related entities?

The sales were made by 5AM Ventures V, L.P., an investment fund. Kush Parmar is a managing member of its general partner and may share voting and investment power, but disclaims beneficial ownership except for his pecuniary interest in the fund.

How many TRDA shares are reported as still held by affiliated entities after these sales?

A related fund, 5AM Opportunities I, L.P., is reported as indirectly holding 1,093,313 Entrada Therapeutics shares. Parmar is a managing member of that fund’s general partner and similarly disclaims beneficial ownership beyond his pecuniary interest.

Does this TRDA Form 4 mention a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirmative, and the footnotes do not describe a trading plan. The transactions are therefore not explicitly identified here as being executed under a pre-arranged Rule 10b5-1 plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/10/2026 - 07:55 PM Accepted by SEC EDGAR 08/10/2026 - 07:54 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PARMAR KUSH

(Last) (First) (Middle)

C/O 5AM VENTURE MANAGEMENT, LLC

4 EMBARCADERO CENTER, SUITE 3110

(Street)

SAN FRANCISCO CALIFORNIA 94111

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Entrada Therapeutics, Inc. [ TRDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/06/2026		S		10,494	D	$7(1)	2,836,098	I	By 5AM Ventures V, L.P.(2)
Common Stock	08/07/2026		S		52,317	D	$6.85(3)	2,783,781	I	By 5AM Ventures V, L.P.
Common Stock	08/10/2026		S		92,444	D	$7(4)	2,691,337	I	By 5AM Ventures V, L.P.(2)
Common Stock								1,093,313	I	By 5AM Opportunities I, L.P.(5)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.90 to $7.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. Shares are held by 5AM Ventures V, L.P. ("5AM V"). 5AM Partners V, LLC ("5AM Partners") is the sole general partner of 5AM V. Kush M. Parmar, M.D., Ph.D. is a managing member of 5AM Partners and may be deemed to share voting and investment power over the shares held by 5AM V. Dr. Parmar disclaims beneficial ownership of the shares held by 5AM V except to the extent of his pecuniary interest therein.

3. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $6.80 to $7.01 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $6.84 to $7.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

5. Shares are held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Kush M. Parmar, M.D., Ph.D. is a managing member of Opportunities GP and may be deemed to share voting and investment power over the shares held by Opportunities. Dr. Parmar disclaims beneficial ownership of the shares held by Opportunities except to the extent of his pecuniary interest therein.

	/s/ Kush Parmar	08/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)